TNF and rheumatoid arthritis: A cost-effectiveness study of the treatment for patients with RA and cDMARD-IR and patients with inadequate response to anti-TNF bDMARDs demonstrated that tofacitinib was frequently used for patients with cDMARD-IR and that it was associated with cost-savings (€ -337,489/quality-adjusted life year gained) in patients with an inadequate response to anti-TNF .37